UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Analysts

UroGen Pharma Ltd. (NASDAQ:URGN) has received a consensus rating of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $38.20.

A number of brokerages have commented on URGN. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research note on Monday, March 10th. HC Wainwright cut their price target on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock.

Insider Buying and Selling

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of URGN. KLP Kapitalforvaltning AS purchased a new position in UroGen Pharma during the 4th quarter worth approximately $59,000. Lazard Asset Management LLC purchased a new position in UroGen Pharma during the 4th quarter worth approximately $67,000. Aquatic Capital Management LLC purchased a new position in UroGen Pharma during the 4th quarter worth approximately $101,000. BNP Paribas Financial Markets grew its holdings in shares of UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of UroGen Pharma during the 4th quarter valued at $126,000. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Stock Performance

Shares of URGN stock opened at $11.07 on Friday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The business has a 50 day moving average of $10.45 and a two-hundred day moving average of $11.65. UroGen Pharma has a 52 week low of $9.03 and a 52 week high of $20.70. The company has a market cap of $259.64 million, a P/E ratio of -3.51 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. As a group, analysts anticipate that UroGen Pharma will post -3.12 EPS for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.